Studies to explore how myrcene, other
cannabinoid-based ingredients can treat
Amid growing public and government concerns regarding opioid
use, GBS Global Biopharma, Inc. will conduct preclinical studies on its proprietary chronic-neuropathic pain formulations in collaboration with National Research Council Canada (NRC).
“Providing sustained relief from chronic-neuropathic pain would bring quality of life to tens of millions of patients throughout the world who suffer from conditions such as … peripheral neuropathy.”
Learn  more.